Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) has issued an announcement.
On October 8, 2025, stockholders of 60 Degrees Pharmaceuticals, Inc., following a recommendation from the board, approved an amendment to implement a one-for-four reverse stock split of the company’s common stock, which became effective at 12:01 a.m. Eastern Time on January 20, 2026, after the related certificate of amendment was filed in Delaware. The reverse split, formally announced on January 15, 2026, reduced the number of issued and outstanding common shares from roughly 5.15 million to about 1.29 million, adjusted all outstanding equity-linked securities accordingly, left the par value and authorized share counts unchanged, and was primarily intended to raise the company’s share price to meet Nasdaq’s minimum bid requirement and thereby support the continued listing of its stock, affecting all shareholders proportionally aside from minor rounding for fractional shares.
The most recent analyst rating on (SXTP) stock is a Sell with a $0.56 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Neutral.
The score is held down primarily by very large ongoing losses and persistent negative free cash flow, which outweigh the recent revenue rebound and low leverage. Technicals are broadly bearish with the stock below key moving averages, while valuation remains unattractive due to lack of profitability. A recent strategy update is modestly positive but paired with explicit going-concern and regulatory risks.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010 and headquartered in Washington, D.C. with a subsidiary in Australia, is a pharmaceutical company specializing in developing and commercializing medicines for the treatment and prevention of vector-borne diseases. Its lead product, ARAKODA (tafenoquine), received U.S. Food and Drug Administration approval for malaria prevention in 2018 and is commercially available in the United States and Australia, supported by collaborations with research and academic organizations in both countries.
Average Trading Volume: 55,918
Technical Sentiment Signal: Sell
Current Market Cap: $10.32M
Learn more about SXTP stock on TipRanks’ Stock Analysis page.